Serpine1 (serpin family E member 1) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Serpine1 (serpin family E member 1) Rattus norvegicus
Analyze
Symbol: Serpine1
Name: serpin family E member 1
RGD ID: 3249
Description: Enables protease binding activity and serine-type endopeptidase inhibitor activity. Involved in several processes, including cellular response to cytokine stimulus; cellular response to hormone stimulus; and cellular response to organonitrogen compound. Located in chromaffin granule and extracellular space. Used to study several diseases, including artery disease (multiple); cerebrovascular disease (multiple); diabetes mellitus (multiple); end stage renal disease; and renal fibrosis. Biomarker of several diseases, including acute necrotizing pancreatitis; glomerulosclerosis (multiple); lung disease (multiple); middle cerebral artery infarction; and muscular atrophy. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); autoimmune disease (multiple); liver disease (multiple); lung disease (multiple); and retinal vascular disease (multiple). Orthologous to human SERPINE1 (serpin family E member 1); PARTICIPATES IN oxygen homeostasis pathway; fibrinolysis pathway; hypoxia inducible factor pathway; INTERACTS WITH (S)-colchicine; (S)-naringenin; (S)-nicotine.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: endothelial plasminogen activator inhibitor; PAI; PAI-1; Pai1; PAI1A; Pai1aa; Planh; Plasminogen activator inhibitor; plasminogen activator inhibitor 1; RATPAI1A; serine (or cysteine) peptidase inhibitor, clade E, member 1; serine (or cysteine) proteinase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; serine (or cysteine) proteinase inhibitor, clade E, member 1; serine (or cysteine) proteinase inhibitor, member 1; serpin E1; serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81225,237,977 - 25,248,356 (+)NCBIGRCr8
mRatBN7.21219,601,272 - 19,611,657 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1219,601,272 - 19,611,657 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1220,739,113 - 20,749,506 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01221,351,819 - 21,362,213 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01220,416,358 - 20,426,756 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01222,641,104 - 22,651,482 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1222,641,104 - 22,651,482 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01224,653,385 - 24,663,763 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41220,931,996 - 20,942,374 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11220,921,607 - 20,931,986 (-)NCBI
Celera1221,377,028 - 21,387,410 (+)NCBICelera
RH 3.4 Map12277.5RGD
Cytogenetic Map12q12NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
abdominal aortic aneurysm  (IMP)
Acquired Protein C Deficiency  (IEP)
Acute Lung Injury  (IDA,IEP)
acute necrotizing pancreatitis  (IEP,ISO)
adult respiratory distress syndrome  (ISO)
Aggressive Fibromatosis  (ISO)
Albuminuria  (ISO)
Alcoholic Fatty Liver  (IEP)
alcoholic liver cirrhosis  (ISO)
allergic rhinitis  (ISO)
amyloidosis  (ISO)
Animal Disease Models  (ISO)
anterolateral myocardial infarction  (ISO)
aortic aneurysm  (IMP)
Aortic Remodeling  (IDA)
Arterial Thrombosis  (IEP)
asthma  (IEP,ISO)
atherosclerosis  (ISO)
autistic disorder  (ISO)
bacterial pneumonia  (ISO)
Banti's Syndrome  (ISO)
Behcet's disease  (ISO)
Brain Hypoxia-Ischemia  (ISO)
brain ischemia  (IDA)
breast cancer  (ISO)
bronchopulmonary dysplasia  (ISO)
Cardiac Fibrosis  (IDA,IEP)
Carotid Artery Injuries  (IEP)
Central Serous Chorioretinopathy  (ISO)
cerebral infarction  (IDA)
Chemical and Drug Induced Liver Injury  (ISO)
cholestasis  (ISO)
Choroidal Neovascularization, Experimental  (IDA,ISO)
Chronic Allograft Nephropathy  (ISO)
chronic obstructive pulmonary disease  (IEP,ISO)
Chronic Relapsing Experimental Autoimmune Encephalomyelitis  (ISO)
congestive heart failure  (ISO)
coronary artery disease  (ISO)
Coronavirus infectious disease  (ISS)
Dermal Fibrosis  (ISO)
diabetes mellitus  (IDA)
diabetic angiopathy  (ISO)
Diabetic Nephropathies  (IDA,IEP,ISO)
diabetic retinopathy  (ISO)
disseminated intravascular coagulation  (IDA,IEP)
end stage renal disease  (IDA,ISO)
Endotoxemia  (IDA,IEP)
Experimental Autoimmune Encephalomyelitis  (ISO)
Experimental Diabetes Mellitus  (ISO)
familial combined hyperlipidemia  (ISO)
familial hypercholesterolemia  (ISO)
familial mediterranean fever  (ISO)
Fetal Growth Retardation  (ISO)
Fever  (ISO)
fibrosarcoma  (ISO)
focal segmental glomerulosclerosis  (IEP,ISO)
Gastrointestinal Hemorrhage  (ISO)
genetic disease  (ISO)
glaucoma  (ISO)
glomerulonephritis  (ISO)
glomerulosclerosis  (IDA,IEP)
graft-versus-host disease  (ISO)
Graves ophthalmopathy  (ISO)
Graves' disease  (ISO)
head and neck squamous cell carcinoma  (ISO)
hematopoietic system disease  (IDA)
Hemorrhage  (IDA,IEP,ISO)
hemorrhagic disease  (ISO)
high grade glioma  (ISO)
Hyaline Membrane Disease  (ISO)
hypertension  (IDA,IEP,ISO)
hyperthyroidism  (ISO)
Insulin Resistance  (IDA,IEP)
interstitial lung disease  (ISO)
Intestinal Polyps  (ISO)
Intestinal Reperfusion Injury  (IDA)
ischemic colitis  (ISO)
Kidney Reperfusion Injury  (ISO)
limited scleroderma  (ISO)
liver cirrhosis  (ISO)
liver disease  (ISO)
Liver Neoplasms  (ISO)
Liver Reperfusion Injury  (IEP)
lung disease  (ISO)
Lung Reperfusion Injury  (IDA,ISO)
macular degeneration  (ISO)
metabolic dysfunction-associated steatotic liver disease  (ISO)
Metabolic Syndrome  (IDA)
middle cerebral artery infarction  (IEP)
Multiple Organ Failure  (IDA)
Multiple Trauma  (IEP)
muscular atrophy  (IEP)
myocardial infarction  (IMP,ISO)
Myocardial Reperfusion Injury  (IDA)
Neointima  (IMP,ISO)
Neovascularization, Pathologic  (ISO)
nephrotic syndrome  (ISO)
nervous system disease  (ISO)
neurilemmoma  (ISO)
Noonan syndrome  (ISO)
obesity  (ISO)
obstructive sleep apnea  (ISO)
oral squamous cell carcinoma  (ISO)
Oxygen-Induced Retinopathy  (IEP,ISO)
Penetrating Wounds  (IEP)
peripheral artery disease  (ISO)
Peritoneal Adhesions  (IDA,IEP)
Peritoneal Fibrosis  (ISO)
placental insufficiency  (ISO)
Plasminogen Activator Inhibitor-1 Deficiency  (ISO)
platelet-type bleeding disorder 10  (ISO)
pleomorphic xanthoastrocytoma  (ISO)
pleurisy  (ISO)
pneumonia  (ISO)
polycystic ovary syndrome  (ISO)
polycythemia  (IEP)
polyneuropathy  (ISO)
portal vein thrombosis  (ISO)
Postoperative Atrial Fibrillation  (ISO)
pre-eclampsia  (ISO)
Pregnancy Complications  (ISO)
proliferative diabetic retinopathy  (ISO)
Prostatic Neoplasms  (ISO)
pulmonary fibrosis  (IEP,IMP,ISO)
pulmonary hypertension  (IDA,ISO)
Radiation Nephropathy  (IEP)
relapsing-remitting multiple sclerosis  (ISO)
renal fibrosis  (IDA,IEP)
respiratory allergy  (ISO)
retinal vein occlusion  (ISO)
retinopathy of prematurity  (ISO)
rhinitis  (ISO)
Rhinosinusitis  (ISO)
sciatic neuropathy  (IDA)
Sepsis  (IDA,ISO)
sleep apnea  (ISO)
steatotic liver disease  (ISO)
Stomach Neoplasms  (ISO)
Stroke  (ISO)
Sudden Hearing Loss  (ISO)
systemic scleroderma  (ISO)
thoracic aortic aneurysm  (ISO)
thrombosis  (ISO)
toxic shock syndrome  (ISO)
transient cerebral ischemia  (IDA)
type 2 diabetes mellitus  (IDA,IEP,ISO)
ureteral obstruction  (IDA,IEP,ISO)
urinary bladder cancer  (ISO)
uveal melanoma  (ISO)
Vascular Depression  (IDA)
Vascular Remodeling  (ISO)
Venous Thromboembolism  (ISO)
Venous Thrombosis  (IEP,IMP,ISO)
Ventilator-Induced Lung Injury  (IEP)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-catechin  (ISO)
(R)-adrenaline  (ISO)
(R)-lipoic acid  (ISO)
(R)-noradrenaline  (ISO)
(S)-colchicine  (EXP)
(S)-naringenin  (EXP)
(S)-nicotine  (EXP,ISO)
1,1-dichloroethene  (ISO)
1,10-phenanthroline  (ISO)
1,2,4-trimethylbenzene  (EXP)
1,2-dimethylhydrazine  (ISO)
1-chloro-2,4-dinitrobenzene  (ISO)
1-naphthyl isothiocyanate  (EXP,ISO)
1-nitropyrene  (ISO)
15-deoxy-Delta(12,14)-prostaglandin J2  (EXP)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-hydroxy-17-methylestra-4,9,11-trien-3-one  (ISO)
17beta-hydroxy-5alpha-androstan-3-one  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (EXP,ISO)
2,2,2-tetramine  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-diaminotoluene  (ISO)
2,4-dichlorophenol  (ISO)
2,6-di-tert-butyl-4-methylphenol  (ISO)
2-amino-2-deoxy-D-galactopyranose  (EXP)
2-butoxyethanol  (ISO)
2-chloroethanol  (ISO)
2-hydroxypropanoic acid  (ISO)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid  (ISO)
3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione  (EXP)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
3-methylcholanthrene  (ISO)
3-phenylprop-2-enal  (ISO)
4'-Methoxychalcone  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-aminophenol  (EXP)
4-hydroxy-TEMPO  (ISO)
4-nitrophenol  (ISO)
5-aza-2'-deoxycytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
8-Br-cAMP  (ISO)
9-cis-retinoic acid  (ISO)
acetamide  (EXP)
acrolein  (ISO)
adenine  (EXP)
aflatoxin B1  (EXP,ISO)
aldehydo-D-glucose  (EXP,ISO)
aldosterone  (EXP,ISO)
all-trans-retinoic acid  (ISO)
Allylamine  (EXP)
aminoguanidine  (EXP,ISO)
ammonium chloride  (EXP)
amphibole asbestos  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (EXP,ISO)
antimonite  (ISO)
apocynin  (ISO)
arecoline  (ISO)
aristolochic acid A  (ISO)
aristolochic acids  (EXP)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (EXP,ISO)
aspalathin  (ISO)
atazanavir sulfate  (ISO)
atorvastatin calcium  (EXP)
atrazine  (EXP,ISO)
Aurin  (ISO)
azathioprine  (ISO)
barium chloride  (EXP)
benazepril  (EXP,ISO)
benzalkonium chloride  (ISO)
benzo[a]pyrene  (ISO)
benzo[b]fluoranthene  (ISO)
Benzo[k]fluoranthene  (ISO)
beta-naphthoflavone  (EXP,ISO)
bezafibrate  (ISO)
bicalutamide  (ISO)
bilirubin IXalpha  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
Bisphenol A diglycidyl ether  (EXP)
Bisphenol B  (ISO)
bisphenol F  (ISO)
bleomycin A2  (ISO)
bortezomib  (EXP)
busulfan  (ISO)
butan-1-ol  (ISO)
butanal  (ISO)
Butylbenzyl phthalate  (ISO)
butyric acid  (EXP)
C.I. Natural Red 20  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
cadmium selenide  (ISO)
calciol  (ISO)
calcitriol  (ISO)
calcium atom  (ISO)
calcium(0)  (ISO)
camostat  (EXP)
cannabidiol  (ISO)
cantharidin  (ISO)
capsaicin  (ISO)
captan  (ISO)
carbamazepine  (ISO)
carbofuran  (EXP)
carbon nanotube  (ISO)
carbonyl cyanide p-trifluoromethoxyphenylhydrazone  (ISO)
chenodeoxycholic acid  (ISO)
chloroform  (EXP)
chloropicrin  (ISO)
chloroquine  (ISO)
chlorpyrifos  (ISO)
choline  (ISO)
chrysene  (ISO)
ciglitazone  (ISO)
cis-caffeic acid  (ISO)
cisplatin  (EXP,ISO)
clofibrate  (ISO)
clofibric acid  (ISO)
Clofop  (ISO)
clothianidin  (ISO)
cobalt atom  (ISO)
cobalt dichloride  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
crocidolite asbestos  (ISO)
CU-O LINKAGE  (ISO)
curcumin  (ISO)
cyanocob(III)alamin  (ISO)
cycloheximide  (EXP,ISO)
cyclophosphamide  (EXP)
cyclosporin A  (EXP,ISO)
D-glucose  (EXP,ISO)
daunorubicin  (EXP,ISO)
decabromodiphenyl ether  (EXP)
deoxycholic acid  (ISO)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diarsenic trioxide  (EXP,ISO)
dibenz[a,h]anthracene  (ISO)
dibenzofuran  (EXP)
dibutyl phthalate  (EXP,ISO)
dichlorine  (EXP)
dichloroacetic acid  (ISO)
diclofenac  (EXP,ISO)
dicrotophos  (ISO)
Didecyldimethylammonium  (ISO)
dieldrin  (ISO)
dienogest  (ISO)
diethyl phthalate  (ISO)
diisobutyl phthalate  (ISO)
diisononyl phthalate  (ISO)
dinitrogen  (ISO)
dioxygen  (EXP,ISO)
dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate  (ISO)
diquat  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
efavirenz  (ISO)
emodin  (ISO)
enalapril  (EXP)
enalaprilat dihydrate  (EXP)
endosulfan  (EXP)
entinostat  (ISO)
eplerenone  (EXP)
eprosartan  (EXP)
Ethyl icosapentate  (EXP)
ethyl methanesulfonate  (ISO)
famotidine  (EXP)
fenofibrate  (EXP,ISO)
fipronil  (EXP)
flutamide  (EXP)
folic acid  (ISO)
formaldehyde  (ISO)
fosinopril  (EXP)
fructose  (EXP)
fulvestrant  (ISO)
fumonisin B1  (ISO)
geldanamycin  (ISO)
gemfibrozil  (ISO)
genistein  (EXP,ISO)
gentamycin  (EXP)
gestodene  (ISO)
Gingerenone A  (ISO)
glucose  (EXP,ISO)
glycochenodeoxycholic acid  (ISO)
glycocholic acid  (ISO)
glycodeoxycholic acid  (ISO)
Goe 6976  (EXP)
gold atom  (ISO)
gold(0)  (ISO)
graphite  (EXP)
guanethidine  (ISO)
GW 501516  (ISO)
heparin  (EXP)
hexadecanoic acid  (ISO)
Hexadimethrine bromide  (EXP)
Honokiol  (EXP)
hydralazine  (EXP)
hydrochlorothiazide  (EXP)
hydrogen chloride  (ISO)
hydrogen peroxide  (EXP,ISO)
hydrogen sulfide  (ISO)
hydroxychloroquine  (ISO)
hydroxyl  (ISO)
hypochlorous acid  (ISO)
indirubin-3'-monoxime  (ISO)
indometacin  (ISO)
ionomycin  (EXP)
iron(III) citrate  (ISO)
isobutanol  (ISO)
isoprenaline  (EXP)
isorhamnetin  (ISO)
isotretinoin  (EXP)
ivermectin  (ISO)
kainic acid  (ISO)
L-ascorbic acid  (EXP)
L-methionine  (ISO)
lactacystin  (ISO)
lead diacetate  (ISO)
leflunomide  (ISO)
levonorgestrel  (ISO)
linoleic acid  (ISO)
lipoic acid  (ISO)
lipopolysaccharide  (EXP,ISO)
magnesium atom  (ISO)
magnesium dichloride  (ISO)
manganese atom  (ISO)
manganese(0)  (ISO)
manganese(II) chloride  (EXP)
mangiferin  (EXP)
Mecamylamine  (ISO)
medroxyprogesterone acetate  (ISO)
meglumine amidotrizoate  (EXP)
mercury dibromide  (ISO)
mercury dichloride  (EXP)
metaproterenol  (EXP)
metformin  (EXP)
methamphetamine  (ISO)
methapyrilene  (EXP)
methimazole  (EXP)
methotrexate  (ISO)
methyl beta-cyclodextrin  (ISO)
methyl methanesulfonate  (ISO)
methylmercury chloride  (ISO)
methylparaben  (ISO)
metyrapone  (EXP)
mifepristone  (EXP,ISO)
mitomycin C  (ISO)
mitoxantrone  (EXP)
mono(2-ethylhexyl) phthalate  (ISO)
monocrotaline  (ISO)
Muraglitazar  (EXP)
N-acetylsphingosine  (ISO)
N-methyl-N'-nitro-N-nitrosoguanidine  (EXP)
N-nitrosodiethylamine  (EXP,ISO)
N-Nitrosopyrrolidine  (ISO)
N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine  (EXP)
naphthalene  (ISO)
naphthalenes  (EXP)
nefazodone  (ISO)
nickel atom  (ISO)
nickel dichloride  (EXP,ISO)
nickel subsulfide  (ISO)
nickel sulfate  (ISO)
niclosamide  (ISO)
nicotine  (EXP,ISO)
nicotinic acid  (EXP,ISO)
nonanedioic acid  (ISO)
Nonidet P-40  (ISO)
norethisterone  (ISO)
notoginsenoside R1  (ISO)
NSC 23766  (ISO)
obeticholic acid  (ISO)
ochratoxin A  (EXP)
octadecanoic acid  (ISO)
oleic acid  (ISO)
Olmesartan medoxomil  (EXP)
orciprenaline  (EXP)
oxaliplatin  (EXP)
ozone  (EXP,ISO)
p-chloromercuribenzoic acid  (ISO)
paclitaxel  (ISO)
palbociclib  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP,ISO)
paricalcitol  (ISO)
pentane-2,3-dione  (EXP)
Pentoxifylline  (EXP)
perfluorobutyric acid  (ISO)
perfluorononanoic acid  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
perfluoropentanoic acid  (ISO)
Phenelzine  (ISO)
phenethyl isothiocyanate  (ISO)
phenformin  (EXP)
phenobarbital  (ISO)
phentolamine  (ISO)
phenylephrine  (EXP,ISO)
phenylmercury acetate  (ISO)
phenytoin  (ISO)
phorbol 13-acetate 12-myristate  (EXP,ISO)
phosgene  (ISO)
phosphane  (EXP)
phosphorus atom  (ISO)
phosphorus(.)  (ISO)
Phytolaccoside E  (ISO)
pioglitazone  (EXP,ISO)
pirfenidone  (EXP,ISO)
pirinixic acid  (ISO)
poly(I:C)  (ISO)
potassium chloride  (EXP)
potassium dichromate  (ISO)
procyanidin B3  (ISO)
progesterone  (EXP,ISO)
propanal  (ISO)
pyrrolidine dithiocarbamate  (ISO)
quercetin  (ISO)
quercetin 3-O-beta-D-glucofuranoside  (EXP)
quercetin 3-O-beta-D-glucopyranoside  (EXP)
quinolin-8-ol  (ISO)
rac-lactic acid  (ISO)
raloxifene  (ISO)
ranitidine  (EXP)
reserpine  (EXP)
resveratrol  (EXP,ISO)
rifampicin  (ISO)
rimonabant  (EXP)
rosmarinic acid  (ISO)
rotenone  (EXP)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (EXP)
salvianolic acid B  (ISO)
saralasin  (EXP)
SB 203580  (ISO)
SB 431542  (ISO)
Securinine  (ISO)
serpentine asbestos  (ISO)
Shikonin  (ISO)
silicon atom  (ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
simvastatin  (EXP,ISO)
sirolimus  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium dichromate  (ISO)
sodium dodecyl sulfate  (ISO)
Soman  (EXP)
sotorasib  (ISO)
spironolactone  (ISO)
streptozocin  (EXP,ISO)
succimer  (ISO)
sulforaphane  (ISO)
sulindac sulfide  (ISO)
sunitinib  (ISO)
Sunset Yellow FCF  (ISO)
superoxide  (ISO)
tacrolimus hydrate  (EXP)
tamoxifen  (ISO)
tartrazine  (ISO)
taurocholic acid  (ISO)
telmisartan  (EXP,ISO)
temozolomide  (ISO)
tert-butyl hydroperoxide  (ISO)
Tesaglitazar  (EXP)
testosterone  (ISO)
tetrachloromethane  (EXP,ISO)
tetraphene  (ISO)
thiacloprid  (ISO)
thimerosal  (ISO)
thioacetamide  (EXP)
thiophanate-methyl  (ISO)
tibolone  (ISO)
titanium dioxide  (EXP,ISO)
topotecan  (EXP,ISO)
trametinib  (ISO)
trans-caffeic acid  (ISO)
triadimefon  (ISO)
triamterene  (EXP)
trichloroethene  (EXP,ISO)
trichostatin A  (ISO)
triclosan  (ISO)
trimellitic anhydride  (ISO)
tris(2-butoxyethyl) phosphate  (ISO)
troglitazone  (EXP,ISO)
trovafloxacin  (ISO)
undecane  (EXP)
usnic acid  (ISO)
valproic acid  (EXP,ISO)
valsartan  (EXP,ISO)
vincaleukoblastine  (EXP,ISO)
vinclozolin  (EXP)
vincristine  (EXP,ISO)
vitamin E  (EXP)
wortmannin  (ISO)
zearalenone  (ISO)
zinc atom  (EXP,ISO)
zinc molecular entity  (ISO)
zinc oxide  (EXP)
zinc pyrithione  (ISO)
zinc(0)  (EXP,ISO)
ziram  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
angiogenesis  (IEA,ISO)
cellular response to aldosterone  (IEP)
cellular response to angiotensin  (IEP)
cellular response to ATP  (IEP)
cellular response to cAMP  (IEP)
cellular response to cGMP  (IEP)
cellular response to cycloheximide  (IEP)
cellular response to dexamethasone stimulus  (IEP)
cellular response to fibroblast growth factor stimulus  (IEP)
cellular response to follicle-stimulating hormone stimulus  (IEP)
cellular response to glucagon stimulus  (IEP)
cellular response to glucose stimulus  (IEP)
cellular response to gravity  (IEP)
cellular response to growth factor stimulus  (IEP)
cellular response to hydrogen peroxide  (IEP)
cellular response to hypoxia  (IEP)
cellular response to insulin stimulus  (IEP)
cellular response to interleukin-1  (IDA)
cellular response to leukemia inhibitory factor  (IEP)
cellular response to lipopolysaccharide  (IEA,IEP,ISO)
cellular response to low-density lipoprotein particle stimulus  (IEP)
cellular response to mechanical stimulus  (IEP)
cellular response to metal ion  (IEP)
cellular response to nerve growth factor stimulus  (IEP)
cellular response to nicotine  (IEP)
cellular response to organic cyclic compound  (IEP)
cellular response to platelet-derived growth factor stimulus  (IEP)
cellular response to potassium ion  (IEP)
cellular response to resveratrol  (IEP)
cellular response to transforming growth factor beta stimulus  (IEP,ISO)
cellular response to xenobiotic stimulus  (IDA)
decidualization  (IEP)
defense response to Gram-negative bacterium  (IEA,ISO)
dentinogenesis  (IEA,ISO)
female gonad development  (IDA)
mast cell activation  (IEP)
negative regulation of cell adhesion mediated by integrin  (IEA,ISO)
negative regulation of cell migration  (IDA,IMP,ISO)
negative regulation of endopeptidase activity  (IDA)
negative regulation of endothelial cell apoptotic process  (IEA,ISO)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors  (IEA,ISO)
negative regulation of fibrinolysis  (IEA,ISO)
negative regulation of gene expression  (IMP)
negative regulation of plasminogen activation  (IBA,IEA,ISO)
negative regulation of smooth muscle cell migration  (IEA,ISO)
negative regulation of smooth muscle cell-matrix adhesion  (IEA,ISO)
negative regulation of vascular wound healing  (IBA,IEA,ISO)
placenta development  (ISO)
positive regulation of angiogenesis  (IEA,ISO)
positive regulation of blood coagulation  (ISO)
positive regulation of calcium ion import  (IMP)
positive regulation of coagulation  (IMP)
positive regulation of collagen biosynthetic process  (IMP)
positive regulation of epithelium regeneration  (IMP)
positive regulation of fibroblast proliferation  (IMP)
positive regulation of gene expression  (IMP)
positive regulation of inflammatory response  (ISO)
positive regulation of interleukin-8 production  (IEA,ISO)
positive regulation of keratinocyte migration  (IMP)
positive regulation of leukotriene production involved in inflammatory response  (IEA,ISO)
positive regulation of monocyte chemotaxis  (IEA,ISO)
positive regulation of odontoblast differentiation  (IEA,ISO)
positive regulation of receptor-mediated endocytosis  (IEA,IMP,ISO)
regulation of angiogenesis  (ISO)
regulation of cell population proliferation  (ISO)
replicative senescence  (IEA,ISO,ISS)
response to cytokine  (IEP)
response to epidermal growth factor  (IEP)
response to estrogen  (IEP)
response to hyperoxia  (IEP)
response to laminar fluid shear stress  (IEP)
response to lipopolysaccharide  (IEP)
response to nutrient levels  (IEP)
response to reactive oxygen species  (IEP)
response to starvation  (IEP)
response to transforming growth factor beta  (IEP)
tissue regeneration  (IEP)

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
# Reference Title Reference Citation
1. The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21.
2. Modulation of retinal capillary endothelial cells by Muller glial cell-derived factors. Abukawa H, etal., Mol Vis. 2009;15:451-7. Epub 2009 Feb 27.
3. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Allaire E, etal., Circulation. 1998 Jul 21;98(3):249-55.
4. Osteoblasts display receptors for and responses to leukemia-inhibitory factor. Allan EH, etal., J Cell Physiol. 1990 Oct;145(1):110-9.
5. Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS-induced DIC model rats. Asakura H, etal., J Thromb Haemost. 2005 May;3(5):1050-5.
6. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Ashitani J, etal., Intern Med. 2002 Mar;41(3):181-5.
7. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. Askari AT, etal., J Exp Med. 2003 Mar 3;197(5):615-24.
8. Mutant matrix metalloproteinase-9 reduces postoperative peritoneal adhesions in rats. Atta H, etal., Int J Surg. 2016 Feb;26:58-63. doi: 10.1016/j.ijsu.2015.12.065. Epub 2016 Jan 12.
9. Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension. Avendano MS, etal., Br J Pharmacol. 2016 May;173(9):1541-55. doi: 10.1111/bph.13457. Epub 2016 Mar 21.
10. Secretion of cardiac plasminogen activator during hypoxia-induced right ventricular hypertrophy. Bansal DD, etal., J Mol Cell Cardiol. 1997 Nov;29(11):3105-14.
11. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. Barazzone C, etal., J Clin Invest. 1996 Dec 15;98(12):2666-73.
12. Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy. Basu A, etal., Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4974-81. doi: 10.1167/iovs.09-3619. Epub 2009 May 14.
13. Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension. Bayan K, etal., J Thromb Thrombolysis. 2009 Jul;28(1):57-62. doi: 10.1007/s11239-008-0244-8. Epub 2008 Aug 7.
14. The C766T low-density lipoprotein receptor related protein polymorphism and coronary artery disease, plasma lipoproteins, and longevity in the Czech population. Benes P, etal., J Mol Med. 2001 Apr;79(2-3):116-20.
15. Plasminogen activator inhibitor-1 gene polymorphism in Iranian Azeri Turkish patients with FMF disease and its association with amyloidosis. Bonyadi M, etal., Eur J Pediatr. 2013 Jan;172(1):91-8. doi: 10.1007/s00431-012-1844-z. Epub 2012 Oct 5.
16. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Bouchie JL, etal., Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1771-9.
17. P2Y receptor regulation of PAI-1 expression in vascular smooth muscle cells. Bouchie JL, etal., Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):866-73.
18. Pioglitazone in adult rats reverses immediate postnatal overfeeding-induced metabolic, hormonal, and inflammatory alterations. Boullu-Ciocca S, etal., Endocrine. 2015 Dec;50(3):608-19. doi: 10.1007/s12020-015-0657-z. Epub 2015 Jun 18.
19. The serpin protease-nexin 1 is present in rat aortic smooth muscle cells and is upregulated in L-NAME hypertensive rats. Bouton MC, etal., Arterioscler Thromb Vasc Biol 2003 Jan 1;23(1):142-7.
20. Uridine triphosphate (UTP) induces profibrotic responses in cardiac fibroblasts by activation of P2Y2 receptors. Braun OO, etal., J Mol Cell Cardiol. 2010 Sep;49(3):362-9. doi: 10.1016/j.yjmcc.2010.05.001. Epub 2010 May 13.
21. Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids. Brims FJ, etal., Thorax. 2009 Dec;64(12):1037-43. Epub 2009 Aug 23.
22. Modulation of plasminogen activator inhibitor type-1 biosynthesis in vitro and in vivo with oligo(nucleoside phosphorothioate)s and related constructs. Buczko W, etal., Pharmacol Ther. 1997 Oct-Dec;76(1-3):161-75.
23. Treatment with oestrogen-receptor agonists or oxytocin in conjunction with exercise protects against post-menopausal myocardial infarction in rats. Bulut EC, etal., Exp Physiol. 2016 Mar 9. doi: 10.1113/EP085708.
24. Fructose-induced inflammation, insulin resistance and oxidative stress: A liver pathological triad effectively disrupted by lipoic acid. Castro MC, etal., Life Sci. 2015 Sep 15;137:1-6. doi: 10.1016/j.lfs.2015.07.010. Epub 2015 Jul 17.
25. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. Chang ML, etal., J Gastroenterol Hepatol. 2015 Feb;30(2):329-36. doi: 10.1111/jgh.12705.
26. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. Chang W, etal., J Biol Chem. 2010 Mar 12;285(11):8196-206. Epub 2010 Jan 8.
27. Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Charakida M, etal., Atherosclerosis. 2009 Jun;204(2):532-7. doi: 10.1016/j.atherosclerosis.2008.09.025. Epub 2008 Oct 5.
28. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. Chen CH, etal., J Lab Clin Med. 2003 Aug;142(2):100-5.
29. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. Chen SC, etal., J Urol. 2009 Jan;181(1):336-42. Epub 2008 Nov 17.
30. Suppression of plasminogen activator inhibitor-1 by inhaled nitric oxide attenuates the adverse effects of hyperoxia in a rat model of acute lung injury. Chen Y, etal., Thromb Res. 2015 Jul;136(1):131-8. doi: 10.1016/j.thromres.2015.04.018. Epub 2015 Apr 22.
31. Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity. Cho KS, etal., Glia. 2013 May;61(5):694-709. doi: 10.1002/glia.22463. Epub 2013 Feb 4.
32. Association of the 4 g/5 g polymorphism of plasminogen activator inhibitor-1 gene with sudden sensorineural hearing loss. A case control study. Cho SH, etal., BMC Ear Nose Throat Disord. 2012 Jun 6;12:5. doi: 10.1186/1472-6815-12-5.
33. Plasminogen activator inhibitor type-1 gene 4G/5G polymorphism in Turkish adult patients with asthma. Cosan D, etal., Genet Test Mol Biomarkers. 2009 Aug;13(4):543-6.
34. Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population. D'Amico M, etal., Gene. 2015 Aug 15;568(1):85-8. doi: 10.1016/j.gene.2015.05.034. Epub 2015 May 16.
35. Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Dan J, etal., Arch Ophthalmol. 2005 Feb;123(2):220-4.
36. In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element. Dichtl W, etal., Thromb Haemost. 2000 Oct;84(4):706-11.
37. CREB binding to the hypoxia-inducible factor-1 responsive elements in the plasminogen activator inhibitor-1 promoter mediates the glucagon effect. Dimova EY, etal., Thromb Haemost. 2007 Aug;98(2):296-303.
38. The prognostic value of BCAR1 in patients with primary breast cancer. Dorssers LC, etal., Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6194-202.
39. [Effects of Shensu II Recipe on the expressions of transforming growth factor-beta1, and plasminogen activator inhibitor-1 in the focal segmental glomerulosclerosis rats]. Dou YT, etal., Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Nov;31(11):1531-7.
40. Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats. Du YG, etal., Chin J Integr Med. 2015 Dec 28.
41. Aortic Remodelling Is Improved by 2,3,5,4'-Tetrahydroxystilbene-2-O-beta-D-glucoside Involving the Smad3 Pathway in Spontaneously Hypertensive Rats. Duan J, etal., Evid Based Complement Alternat Med. 2015;2015:789027. doi: 10.1155/2015/789027. Epub 2015 Nov 29.
42. The role of TNF-a and PAI-1 gene polymorphisms in familial Mediterranean fever. Dundar M, etal., Mod Rheumatol. 2013 Jan;23(1):140-5. doi: 10.1007/s10165-012-0687-9. Epub 2012 Jun 27.
43. Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. East E, etal., Neuropathol Appl Neurobiol. 2008 Apr;34(2):216-30. Epub 2007 Nov 5.
44. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia. Eissa DS and Ahmed TM, Blood Coagul Fibrinolysis. 2013 Mar;24(2):181-8. doi: 10.1097/MBC.0b013e32835b249d.
45. Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis. El Solh AA, etal., Intensive Care Med. 2006 Jan;32(1):110-5. Epub 2005 Nov 12.
46. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Estellés A, etal., Blood. 1994 Jul 1;84(1):143-50.
47. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. Ezzidi I, etal., Diabetes Metab. 2009 Jun;35(3):214-9. doi: 10.1016/j.diabet.2008.12.002. Epub 2009 May 5.
48. Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Fan J, etal., Am J Respir Cell Mol Biol. 2000 Apr;22(4):412-21.
49. Quantitative distribution of a panel of circulating mRNA in preeclampsia versus controls. Farina A, etal., Prenat Diagn. 2006 Dec;26(12):1115-20.
50. Absence of association between polymorphisms in the hemostatic factor pathway genes and carotid intimal medial thickness: the Framingham Heart Study. Fox CS, etal., Stroke. 2004 Mar;35(3):e65-7. Epub 2004 Feb 12.
51. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Funk M, etal., Wien Klin Wochenschr. 2005 Oct;117(19-20):707-10.
52. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
53. Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Globocnik-Petrovic M, etal., Ophthalmologica. 2003 May-Jun;217(3):219-24.
54. Associations of thrombophilia, hypofibrinolysis, and retinal vein occlusion. Glueck CJ, etal., Clin Appl Thromb Hemost. 2005 Oct;11(4):375-89.
55. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Glueck CJ, etal., Metabolism. 2000 Jul;49(7):845-52.
56. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
57. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. Goldberg HJ, etal., J Biol Chem 2002 Sep 13;277(37):33833-41.
58. Smad2-dependent protease nexin-1 overexpression differentiates chronic aneurysms from acute dissections of human ascending aorta. Gomez D, etal., Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2222-32. doi: 10.1161/ATVBAHA.113.301327. Epub 2013 Jun 27.
59. Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors. Gong R, etal., Arthritis Rheum. 2007 May;56(5):1608-17.
60. Evidence of proatherogenic inflammation in polycystic ovary syndrome. González F, etal., Metabolism. 2009 Jul;58(7):954-62. doi: 10.1016/j.metabol.2009.02.022.
61. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Gori AM, etal., Thromb Haemost. 2004 Jul;92(1):54-60.
62. Reactive oxygen species modulate HIF-1 mediated PAI-1 expression: involvement of the GTPase Rac1. Gorlach A, etal., Thromb Haemost. 2003 May;89(5):926-35.
63. Combination of Ligusticum chuanxiong and Radix Paeoniae ameliorats focal cerebral ischemic in MCAO rats via endoplasmic reticulum stress-dependent apoptotic signaling pathway. Gu J, etal., J Ethnopharmacol. 2016 Apr 20. pii: S0378-8741(16)30217-3. doi: 10.1016/j.jep.2016.04.024.
64. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-beta in rat mesangial cells. Guo B, etal., Kidney Int. 2005 Sep;68(3):972-84.
65. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease. Gurgey A, etal., Blood Coagul Fibrinolysis. 2003 Feb;14(2):121-4.
66. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Gutierrez LS, etal., Cancer Res. 2000 Oct 15;60(20):5839-47.
67. Plasminogen activator inhibitor-1 in patients with ischemic stroke. Haapaniemi E, etal., Acta Neurochir Suppl. 2000;76:277-8.
68. Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia. Haitsma JJ, etal., Eur Respir J. 2008 Dec;32(6):1599-606. doi: 10.1183/09031936.00045908. Epub 2008 Sep 3.
69. [Effect of amiloride on the pathology of a rat model of chronic obstructive pulmonary disease]. Han XD, etal., Zhonghua Jie He He Hu Xi Za Zhi. 2007 May;30(5):363-7.
70. The Ayurvedic medicine Salacia oblonga attenuates diabetic renal fibrosis in rats: suppression of angiotensin II/AT1 signaling. He L, etal., Evid Based Complement Alternat Med. 2009 Aug 25.
71. Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences. Heaton JH, etal., J Biol Chem. 1998 Jun 5;273(23):14261-8.
72. Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. Hefler L, etal., J Soc Gynecol Investig. 2004 Jan;11(1):42-4.
73. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum. Higuchi C, etal., Ther Apher Dial. 2005 Apr;9(2):173-81.
74. Establishment of a peritoneal mesothelial cell line from a transgenic rat harbouring the temperature-sensitive simian virus 40 large T-antigen gene. Hotta Y, etal., Nephrol Dial Transplant. 2010 Jan 18.
75. Tissue-type plasminogen activator depletion affects the nasal mucosa matrix reconstruction in allergic rhinitis mice. Hua H, etal., Allergol Immunopathol (Madr). 2011 Jul-Aug;39(4):206-11. doi: 10.1016/j.aller.2010.09.010. Epub 2011 Feb 19.
76. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. Huang Y, etal., J Clin Invest. 2003 Aug;112(3):379-88.
77. Potentiating effect of endothelial cells on astrocytic plasminogen activator inhibitor type-1 gene expression in an in vitro model of the blood-brain barrier. Hultman K, etal., Neuroscience. 2010 Mar 17;166(2):408-15. doi: 10.1016/j.neuroscience.2010.01.002. Epub 2010 Jan 6.
78. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. Hundsdorfer B, etal., J Craniomaxillofac Surg. 2005 Jun;33(3):191-6. Epub 2005 Apr 22.
79. Interleukin-1-mediated regulation of plasminogen activation in pregnant mare serum gonadotropin-primed rat granulosa cells is independent of prostaglandin production. Hurwitz A, etal., J Soc Gynecol Investig. 1995 Sep-Oct;2(5):691-9.
80. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Iijima H, etal., Am J Ophthalmol. 1999 Apr;127(4):477-8.
81. [A novel function of anti-fibrinolytic factor, PAI-1, in the central nervous system: a possible role as the neurotrophic factor] Imatoh T, etal., Nippon Yakurigaku Zasshi 2002 Nov;120(1):64P-66P.
82. Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome. Imperatore F, etal., Intensive Care Med. 2006 Nov;32(11):1881-8. Epub 2006 Sep 15.
83. Plasminogen activator inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral obstruction in adult rats. Ishidoya S, etal., J Urol. 2002 Mar;167(3):1503-7.
84. A combined immunostimulatory and immunoinhibitory short interference RNA reduces hypercoagulability in a rat model of acute promyelocytic leukaemia. Iversen PO, etal., Thromb Haemost. 2010 Aug;104(2):350-4. doi: 10.1160/TH09-12-0816. Epub 2010 Jun 10.
85. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Izuhara Y, etal., Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):672-7. Epub 2008 Jan 31.
86. Effects of activated protein C on ventilator-induced lung injury in rats. Jiang JS, etal., Respiration. 2010;80(3):246-53. Epub 2010 Jan 28.
87. The anti-fibrinolytic SERPIN, plasminogen activator inhibitor 1 (PAI-1), is targeted to and released from catecholamine storage vesicles. Jiang Q, etal., Blood. 2011 Jun 30;117(26):7155-63. doi: 10.1182/blood-2010-05-287672. Epub 2011 May 19.
88. Low-dose paclitaxel ameliorates renal fibrosis by suppressing transforming growth factor-beta1-induced plasminogen activator inhibitor-1 signaling. Jung ES, etal., Nephrology (Carlton). 2016 Feb 11. doi: 10.1111/nep.12747.
89. The mRNA expressions and immunohistochemistry of factors involved in angiogenesis and lymphangiogenesis in the early stage of rat skin incision wounds. Kameyama H, etal., Leg Med (Tokyo). 2015 Jul;17(4):255-60. doi: 10.1016/j.legalmed.2015.02.007. Epub 2015 Mar 7.
90. Endothelial haemostatic markers in members of families with familial combined hyperlipidemia. Karásek D, etal., Thromb Res. 2009;123(3):466-75. doi: 10.1016/j.thromres.2008.02.011. Epub 2008 Apr 16.
91. t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension. Katta S, etal., Indian J Hum Genet. 2008 May;14(2):37-40.
92. Genistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens. Kelly LA, etal., Thromb Haemost. 2010 Sep 13;104(6).
93. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. Kenichi M, etal., J Lab Clin Med. 2004 Aug;144(2):69-77.
94. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Kietzmann T, etal., Blood 2003 Feb 1;101(3):907-14.
95. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Kietzmann T, etal., Blood. 1999 Dec 15;94(12):4177-85.
96. Regulation of the hypoxia-dependent plasminogen activator inhibitor 1 expression by MAP kinases. Kietzmann T, etal., Thromb Haemost. 2003 Apr;89(4):666-73.
97. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Kim KK, etal., Mol Med. 2003 Jan-Feb;9(1-2):52-6.
98. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1. Kimura H, etal., Kidney Int. 1998 Nov;54(5):1659-69.
99. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. Kobayashi N, etal., J Pharmacol Exp Ther. 2002 May;301(2):459-66.
100. A novel binding factor of 14-3-3beta functions as a transcriptional repressor and promotes anchorage-independent growth, tumorigenicity, and metastasis. Komiya Y, etal., J Biol Chem. 2008 Jul 4;283(27):18753-64. Epub 2008 May 5.
101. Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension. Kouri FM, etal., Int J Biochem Cell Biol. 2008;40(9):1872-82. Epub 2008 Feb 2.
102. Plasmin system regulation in an ovalbumin-induced rat model of asthma. Kucharewicz I, etal., Int Arch Allergy Immunol. 2008;147(3):190-6. Epub 2008 Jul 2.
103. In vivo anticoagulant effect of ethyl pyruvate in endotoxemic rats. Kung CW, etal., Thromb Res. 2011 Jun;127(6):582-8. Epub 2011 Mar 10.
104. High-density rat radiation hybrid maps containing over 24,000 SSLPs, genes, and ESTs provide a direct link to the rat genome sequence. Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7
105. Blockade of cysteine-rich protein 61 attenuates renal inflammation and fibrosis after ischemic kidney injury. Lai CF, etal., Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F581-92. doi: 10.1152/ajprenal.00670.2013. Epub 2014 Jun 11.
106. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. Lambert V, etal., FASEB J. 2001 Apr;15(6):1021-7.
107. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Lambert V, etal., Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2791-7.
108. Effects of Bone Marrow Mesenchymal Stem Cells on Plasminogen Activator Inhibitor-1 and Renal Fibrosis in Rats with Diabetic Nephropathy. Lang H, etal., Arch Med Res. 2016 Mar 24. pii: S0188-4409(16)30002-9. doi: 10.1016/j.arcmed.2016.03.002.
109. Regulation of proteolytic enzymes and inhibitors in two smooth muscle cell phenotypes. Lau HK Cardiovasc Res. 1999 Sep;43(4):1049-59.
110. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Laudes IJ, etal., Am J Pathol. 2002 May;160(5):1867-75.
111. Plasminogen activator inhibitor-1 is expressed in cultured rat Sertoli cells. Le Magueresse-Battistoni B, etal., Biol Reprod. 1998 Sep;59(3):591-8.
112. Cinidium officinale and its Bioactive Compound, Butylidenephthalide, Inhibit Laser-Induced Choroidal Neovascularization in a Rat Model. Lee YM, etal., Molecules. 2015 Nov 19;20(11):20699-708. doi: 10.3390/molecules201119728.
113. Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1. Lemaire R, etal., Arthritis Rheumatol. 2016 Feb;68(2):473-83. doi: 10.1002/art.39443.
114. Differential contributions of platelets and fibrinogen to early coagulopathy in a rat model of hemorrhagic shock. Letson HL and Dobson GP, Thromb Res. 2016 Mar 7;141:58-65. doi: 10.1016/j.thromres.2016.03.007.
115. An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients. Li CF, etal., Fam Cancer. 2007;6(1):89-95.
116. Receptor-associated protein promotes t-PA expression, reduces PAI-1 expression and improves neurorecovery after acute ischemic stroke. Li DD, etal., J Neurol Sci. 2015 Mar 15;350(1-2):84-9. doi: 10.1016/j.jns.2015.02.022. Epub 2015 Feb 17.
117. [Protection of rosiglitazone against renal interstitial lesion and its mechanism]. Lin Q, etal., Zhonghua Yi Xue Za Zhi. 2005 Jun 22;85(23):1618-24.
118. Elevated urinary urea by high-protein diet could be one of the inducements of bladder disorders. Liu M, etal., J Transl Med. 2016 Feb 16;14(1):53. doi: 10.1186/s12967-016-0809-9.
119. Delayed ethanol elimination and enhanced susceptibility to ethanol-induced hepatosteatosis after liver resection. Liu X, etal., World J Gastroenterol. 2014 Dec 28;20(48):18249-59. doi: 10.3748/wjg.v20.i48.18249.
120. [Changes of u-PA and PAI-1 expression in the lung tissue of neonatal rats after inhaling high concentration oxygen] Liu XY and Xue XD, Zhonghua Er Ke Za Zhi. 2008 Jun;46(6):458-63.
121. Plasminogen enhances the secretion of plasminogen activator inhibitor-1 from cultured rat astrocytes. Liu Y, etal., Neurosci Lett. 2000 Mar 24;282(3):137-40.
122. Studies on the role of plasminogen activators and plasminogen activator inhibitor type-1 in rat corpus luteum of pregnancy. Liu YX, etal., Biol Reprod. 1995 Nov;53(5):1131-8.
123. Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation of AMP-activated protein kinase and sirtuin 1 activities. Liu Z, etal., J Diabetes. 2016 May;8(3):324-335. doi: 10.1111/1753-0407.12296. Epub 2015 May 6.
124. Basic mechanisms and regulation of fibrinolysis. Longstaff C and Kolev K, J Thromb Haemost. 2015 Jun;13 Suppl 1:S98-105. doi: 10.1111/jth.12935.
125. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis. Lopes Barreto D, etal., Am J Kidney Dis. 2015 May;65(5):748-53. doi: 10.1053/j.ajkd.2014.10.022. Epub 2014 Dec 17.
126. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Ma D, etal., Blood. 1997 Oct 1;90(7):2738-46.
127. 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Madach K, etal., Crit Care. 2010;14(2):R79. Epub 2010 Apr 29.
128. Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC). Magnussen S, etal., PLoS One. 2014 Jul 7;9(7):e101895. doi: 10.1371/journal.pone.0101895. eCollection 2014.
129. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Mansfield MW, etal., Thromb Haemost. 1994 Jun;71(6):731-6.
130. Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing. Maquerlot F, etal., Am J Pathol. 2006 Nov;169(5):1624-32.
131. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Margaglione M, etal., Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):152-6.
132. Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study. Maser RE, etal., J Diabetes Complications. 1997 Jul-Aug;11(4):243-9.
133. Effects of combination PPARgamma agonist and angiotensin receptor blocker on glomerulosclerosis. Matsushita K, etal., Lab Invest. 2016 Mar 21. doi: 10.1038/labinvest.2016.42.
134. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Matsushita M, etal., Clin Exp Immunol. 2005 Mar;139(3):429-38.
135. Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional results of the Cleveland Family Study. Mehra R, etal., Am J Respir Crit Care Med. 2010 Sep 15;182(6):826-33. Epub 2010 May 27.
136. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome. Mehta P and Parker RI, J Pediatr Hematol Oncol. 2010 Oct;32(7):532-6. doi: 10.1097/MPH.0b013e3181e0d152.
137. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample. Meigs JB, etal., Obesity (Silver Spring). 2006 May;14(5):753-8.
138. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
139. Aortic Length Changes During Abdominal Aortic Aneurysm Formation, Expansion and Stabilisation in a Rat Model. Michineau S, etal., Eur J Vasc Endovasc Surg. 2010 Jun 14.
140. Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Milbrandt EB, etal., Mol Med. 2009 Nov-Dec;15(11-12):438-45. Epub 2009 Sep 8.
141. TGF-beta1 and Serpine 1 expression changes in traumatic deep vein thrombosis. Mo JW, etal., Genet Mol Res. 2015 Oct 30;14(4):13835-42. doi: 10.4238/2015.October.29.3.
142. Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves blood coagulation abnormalities and dysfunction of vascular endothelial cells in Otsuka Long-Evans Tokushima fatty rats. Mori Y, etal., Endocr J. 2003 Oct;50(5):603-11.
143. The induction of the immediate-early-genes Egr-1, PAI-1 and PRL-1 during liver regeneration in surgical models is related to increased portal flow. Mueller L, etal., J Hepatol. 2002 Nov;37(5):606-12.
144. Transcriptional regulation of plasminogen activator inhibitor-1 by transforming growth factor-beta, activin A and microphthalmia-associated transcription factor. Murakami M, etal., Cell Signal. 2006 Feb;18(2):256-65. Epub 2005 Jun 14.
145. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Mutoh M, etal., Carcinogenesis. 2008 Apr;29(4):824-9. doi: 10.1093/carcin/bgn028. Epub 2008 Feb 6.
146. Plasminogen activator inhibitor type 1 up-regulation is associated with skeletal muscle atrophy and associated fibrosis. Naderi J, etal., Am J Pathol. 2009 Aug;175(2):763-71. Epub 2009 Jul 2.
147. Protective effects of vascular endothelial growth factor on intestinal epithelial apoptosis and bacterial translocation in experimental severe acute pancreatitis. Nakajima T, etal., Pancreas. 2007 May;34(4):410-6.
148. Shear stress induces hepatocyte PAI-1 gene expression through cooperative Sp1/Ets-1 activation of transcription. Nakatsuka H, etal., Am J Physiol Gastrointest Liver Physiol. 2006 Jul;291(1):G26-34. Epub 2006 Feb 23.
149. Characterization of recombinant rat plasminogen activator inhibitor-1 and development of immunological tools for its quantitation. Ngo TH, etal., J Pharm Belg. 1997 Jul-Aug;52(4):165-6.
150. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Ngo TH, etal., Thromb Haemost. 1998 Apr;79(4):808-12.
151. Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats. Nobukata H, etal., Metabolism. 2000 Jul;49(7):912-9.
152. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Offersen BV, etal., Lung Cancer. 2007 Apr;56(1):43-50. Epub 2007 Jan 17.
153. Upregulated expression of transforming growth factor-beta, type IV collagen, and plasminogen activator inhibitor-1 mRNA are decreased after release of unilateral ureteral obstruction. Ogata Y, etal., Tohoku J Exp Med. 2002 Jul;197(3):159-68.
154. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Oikawa T, etal., Kidney Int. 1997 Jan;51(1):164-72.
155. Extinguishing Egr-1-dependent inflammatory and thrombotic cascades after lung transplantation. Okada M, etal., FASEB J. 2001 Dec;15(14):2757-9. Epub 2001 Oct 15.
156. Role of microthrombus formation in the development of ischemia/reperfusion-induced liver injury in rats. Okajima K, etal., Thromb Haemost. 2002 Sep;88(3):473-80.
157. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
158. Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis. Onodera H, etal., Tohoku J Exp Med. 1999 Dec;189(4):259-65.
159. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behcet's disease. Orem A, etal., Ann Rheum Dis. 1995 Sep;54(9):726-9.
160. Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in Turkish children with asthma and allergic rhinitis. Ozbek OY, etal., Allergy Asthma Proc. 2009 Jan-Feb;30(1):41-6. Epub 2008 Dec 6.
161. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders. Ozcan MA, etal., Thromb Res. 2003 Jun 1;110(4):243-7.
162. Chinese tuina downregulates the elevated levels of tissue plasminogen activator in sciatic nerve injured Sprague-Dawley rats. Pan F, etal., Chin J Integr Med. 2015 May 13.
163. Effects of Kaixinjieyu, a Chinese herbal medicine preparation, on neurovascular unit dysfunction in rats with vascular depression. Pan J, etal., BMC Complement Altern Med. 2015 Aug 19;15:291. doi: 10.1186/s12906-015-0808-z.
164. Inhibition of retinal neovascularization by intravitreal injection of human rPAI-1 in a rat model of retinopathy of prematurity. Penn JS and Rajaratnam VS, Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5423-9.
165. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Penn JS, etal., Invest Ophthalmol Vis Sci. 2001 Jan;42(1):283-90.
166. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
167. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
168. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Pontrelli P, etal., Transplantation. 2008 Jan 15;85(1):125-34. doi: 10.1097/01.tp.0000296831.91303.9a.
169. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Prabhakaran P, etal., Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L20-8. Epub 2003 May 2.
170. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Pretorius M, etal., Circulation. 2007 Sep 11;116(11 Suppl):I1-7.
171. PAI-1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair. Providence KM and Higgins PJ, J Cell Physiol. 2004 Aug;200(2):297-308.
172. Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model. Qiu P, etal., J Infect Dis. 2013 Sep;208(6):978-89. doi: 10.1093/infdis/jit247. Epub 2013 Jun 3.
173. Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Radenkovic D, etal., Pancreas. 2004 Aug;29(2):152-6.
174. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Renckens R, etal., Blood. 2007 Feb 15;109(4):1593-601. Epub 2006 Oct 10.
175. Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma. Revelo MP, etal., Nephrol Dial Transplant. 2005 Dec;20(12):2812-9. Epub 2005 Oct 12.
176. GOA pipeline RGD automated data pipeline
177. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
178. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
179. Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Ricart JM, etal., Br J Haematol. 2008 May;141(5):716-9. doi: 10.1111/j.1365-2141.2008.07078.x. Epub 2008 Mar 12.
180. Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response. Richardson MA, etal., J Pharmacol Exp Ther. 2008 Apr;325(1):17-26. doi: 10.1124/jpet.107.130609. Epub 2008 Jan 8.
181. Involvement of RAGE, NADPH oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Sangle GV, etal., Endocrinology. 2010 Sep;151(9):4455-66. doi: 10.1210/en.2010-0323. Epub 2010 Jul 14.
182. 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia. Sapru A, etal., Anesthesiology. 2009 May;110(5):1086-91.
183. Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury. Sapru A, etal., Intensive Care Med. 2010 Jan;36(1):157-63. Epub 2009 Oct 24.
184. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Sartori MT, etal., Clin Appl Thromb Hemost. 2003 Oct;9(4):299-307.
185. Local intravascular coagulation and fibrin deposition on intestinal ischemia-reperfusion in rats. Schoots IG, etal., Surgery. 2003 Apr;133(4):411-9.
186. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Sciacca FL, etal., Clin Cancer Res. 2004 Feb 15;10(4):1312-7.
187. The EGF-inducible protein EIP-1 of migrating normal and malignant rat liver epithelial cells is identical to plasminogen activator inhibitor 1 and is a component of the ECM migration tracks. Seebacher T, etal., Exp Cell Res. 1992 Dec;203(2):504-7.
188. Increased Umbilical Cord PAI-1 Levels in Placental Insufficiency Are Associated with Fetal Hypoxia and Angiogenesis. Seferovic MD and Gupta MB, Dis Markers. 2016;2016:7124186. doi: 10.1155/2016/7124186. Epub 2016 Jan 19.
189. The expression of fibrinolytic components in chronic paranasal sinus disease. Sejima T, etal., Am J Rhinol Allergy. 2011 Jan-Feb;25(1):1-6.
190. Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats. Serrano R, etal., Am J Physiol Regul Integr Comp Physiol. 2009 Nov;297(5):R1563-9. doi: 10.1152/ajpregu.00093.2009. Epub 2009 Sep 23.
191. A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage. Simone TM, etal., Cell Signal. 2015 May;27(5):923-33. doi: 10.1016/j.cellsig.2015.01.009. Epub 2015 Jan 22.
192. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas. Sirén V, etal., Acta Neurochir (Wien). 2004 Feb;146(2):111-8. Epub 2003 Dec 22.
193. The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels. Sogutlu Sari E, etal., Cutan Ocul Toxicol. 2014 Jan 22.
194. Plasminogen activation inhibitor concentrations in bronchoalveolar lavage fluid distinguishes ventilator-associated pneumonia from colonization in mechanically ventilated pediatric patients. Srinivasan R, etal., Pediatr Crit Care Med. 2010 May 13.
195. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. Stefansson S, etal., J Biol Chem. 1996 Apr 5;271(14):8215-20.
196. Plasminogen activator inhibitor-1 promoter 4G/5G genotype is not a risk factor for myocardial infarction in a Japanese population. Sugano T, etal., Blood Coagul Fibrinolysis. 1998 Mar;9(2):201-4.
197. Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. Suzuki M, etal., Life Sci. 2002 Nov 22;72(1):59-66.
198. Gene-based anchoring of the rat genetic linkage and cytogenetic maps: new regional localizations, orientation of the linkage groups, and insights into mammalian chromosome evolution. Szpirer C, etal., Mamm Genome 1998 Sep;9(9):721-34
199. Platelet activation independent of pulmonary inflammation contributes to diesel exhaust particulate-induced promotion of arterial thrombosis. Tabor CM, etal., Part Fibre Toxicol. 2016 Feb 9;13(1):6. doi: 10.1186/s12989-016-0116-x.
200. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Takada Y, etal., Thromb Res. 1993 Sep 1;71(5):405-15.
201. Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency. Tanaka T, etal., Mol Cell Biochem. 2007 May;299(1-2):23-35.
202. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Tarnow L, etal., Nephrol Dial Transplant. 2000 May;15(5):625-30.
203. Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Teesalu T, etal., Am J Pathol. 2001 Dec;159(6):2227-37.
204. Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril. Toblli JE, etal., Heart. 2005 Jan;91(1):80-6.
205. Regulation of plasminogen activator inhibitor-1 mRNA accumulation by basic fibroblast growth factor and transforming growth factor-beta1 in cultured rat astrocytes. Treichel JA, etal., J Neurochem. 1998 Nov;71(5):1944-52.
206. Effects of gabexate mesilate on coagulopathy and organ dysfunction in rats with endotoxemia: a potential use of thrombelastography in endotoxin-induced sepsis. Tsai HJ, etal., Blood Coagul Fibrinolysis. 2015 Mar;26(2):175-84. doi: 10.1097/MBC.0000000000000214.
207. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Tsantes AE, etal., Thromb Haemost. 2007 Jun;97(6):907-13.
208. The role of hypercoagulability in ischemic colitis. Tsimperidis AG, etal., Scand J Gastroenterol. 2015 Jul;50(7):848-55. doi: 10.3109/00365521.2015.1010568. Epub 2015 Feb 5.
209. Messenger RNA profiles in liver injury and stress: a comparison of lethal and nonlethal rat models. Tygstrup N, etal., Biochem Biophys Res Commun 2002 Jan 11;290(1):518-25.
210. Graves' orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines. Ujhelyi B, etal., Thyroid. 2012 Apr;22(4):407-14. doi: 10.1089/thy.2011.0248. Epub 2012 Mar 2.
211. Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma. Urano T, etal., Jpn J Physiol. 1993;43(2):221-8.
212. Candidate genetic markers and the risk of restenosis after coronary angioplasty. Volzke H, etal., Clin Sci (Lond). 2004 Jan;106(1):35-42.
213. Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism. Wahrenberg H, etal., Eur J Endocrinol. 2002 May;146(5):607-11.
214. The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study. Wang JJ, etal., Ophthalmology. 2008 Apr;115(4):693-9. Epub 2007 Aug 2.
215. Presence of urokinase plasminogen activator and plasminogen activator inhibitor-1 messenger ribonucleic acids in rat endometrium during decidualization in vivo. Wang S, etal., Biol Reprod. 1996 Sep;55(3):493-7.
216. Aldosterone and TGF-beta(1) synergistically increase PAI-1 expression in hepatic stellate cells of rats. Wang SL, etal., Int J Clin Exp Pathol. 2015 Sep 1;8(9):9845-53. eCollection 2015.
217. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Ware LB, etal., Crit Care Med. 2007 Aug;35(8):1821-8.
218. Glucocorticoids activate TGF-beta induced PAI-1 and CTGF expression in rat hepatocytes. Wickert L, etal., Comp Hepatol. 2007 May 2;6:5.
219. A DNA enzyme against plasminogen activator inhibitor- type 1 (PAI-1) limits neointima formation after angioplasty in an obese diabetic rodent model. Witkowski P, etal., J Cardiovasc Pharmacol. 2007 Dec;50(6):633-40.
220. Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia. Wu J, etal., Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1565-70. doi: 10.1161/ATVBAHA.109.189514. Epub 2009 Jul 2.
221. Procoagulant and fibrinolytic activity after polytrauma in rat. Wu X, etal., Am J Physiol Regul Integr Comp Physiol. 2016 Feb 15;310(4):R323-9. doi: 10.1152/ajpregu.00401.2015. Epub 2015 Dec 2.
222. Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction. Xiang G, etal., J Am Coll Cardiol. 2005 Aug 2;46(3):536-41.
223. Down-regulation of plasminogen activator inhibitor 1 expression promotes myocardial neovascularization by bone marrow progenitors. Xiang G, etal., J Exp Med. 2004 Dec 20;200(12):1657-66. Epub 2004 Dec 13.
224. Resveratrol ameliorates renal injury in spontaneously hypertensive rats by inhibiting renal micro-inflammation. Xue H, etal., Biosci Rep. 2016 Apr 19. pii: BSR20160035.
225. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. Yamada Y, etal., N Engl J Med. 2002 Dec 12;347(24):1916-23.
226. Bactericidal/permeability-increasing protein ameliorates hypercoagulability after hemorrhagic shock. Yamashita M Thromb Res. 1997 Aug 1;87(3):323-9.
227. Effect of intra-abdominal administration of ligustrazine nanoparticles nano spray on postoperative peritoneal adhesion in rat model. Yan S, etal., J Obstet Gynaecol Res. 2015 Dec;41(12):1942-50. doi: 10.1111/jog.12807. Epub 2015 Sep 30.
228. Elevated plasma plasminogen activator inhibitor-1 in CD36 deficiency. Yanai H, etal., Diabetes Care. 2008 Oct;31(10):e72. doi: 10.2337/dc08-1228.
229. Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. Yang D, etal., J Neurosci. 2009 Jul 8;29(27):8669-74.
230. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Ye S, etal., Thromb Haemost. 1995 Sep;74(3):837-41.
231. Cyclic stretch magnitude and duration affect rat alveolar epithelial gene expression. Yerrapureddy A, etal., Cell Physiol Biochem. 2010;25(1):113-22. doi: 10.1159/000272056. Epub 2009 Dec 22.
232. Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats. You YP J Stroke Cerebrovasc Dis. 2016 Apr;25(4):990-7. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.014. Epub 2016 Feb 3.
233. Salvia miltiorrhiza depresses plasminogen activator inhibitor-1 production through inhibition of angiotensin II. Yuan J, etal., Am J Chin Med. 2008;36(5):1005-15.
234. A Selective TGFbeta Ligand Trap Attenuates Pulmonary Hypertension. Yung LM, etal., Am J Respir Crit Care Med. 2016 Apr 26.
235. Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension. Zamarron C, etal., Lung. 2008 May-Jun;186(3):151-6. Epub 2008 Mar 11.
236. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Zeheb R and Gelehrter TD, Gene 1988 Dec 20;73(2):459-68.
237. [Expression of TGF-ß1 and PAI-1 in premature infants with bronchopulmonary dysplasia]. Zhang JF, etal., Zhongguo Dang Dai Er Ke Za Zhi. 2014 Aug;16(8):810-3.
238. Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis. Zhang T, etal., BMC Med. 2013 Jan 2;11:1. doi: 10.1186/1741-7015-11-1.
239. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences Zhang YP and Ma JY, Beijing Da Xue Xue Bao. 2005 Oct 18;37(5):516-9.
240. siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats. Zhang YP, etal., Acta Pharmacol Sin. 2012 Jul;33(7):897-908. doi: 10.1038/aps.2012.39. Epub 2012 Jun 4.
241. An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. Zhang ZH, etal., Sci Rep. 2016 Feb 23;6:22151. doi: 10.1038/srep22151.
242. Temporal profile of tissue plasminogen activator (tPA) and inhibitor expression after transient focal cerebral ischemia. Zhao G, etal., Neuroreport. 2003 Sep 15;14(13):1689-92.
243. Plasma plasminogen activator inhibitor-1 is associated with end-stage proliferative diabetic retinopathy in the Northern Chinese Han population. Zhong ZL and Chen S, Exp Diabetes Res. 2012;2012:350852. doi: 10.1155/2012/350852. Epub 2012 Oct 14.
244. Glibenclamide induces collagen IV catabolism in high glucose-stimulated mesangial cells. Zhu L, etal., Exp Diabetes Res. 2012;2012:183535. Epub 2012 Sep 12.
Additional References at PubMed
PMID:1601887   PMID:1632457   PMID:1695900   PMID:2298740   PMID:2503541   PMID:8508955   PMID:8837777   PMID:9207454   PMID:9386191   PMID:10902815   PMID:11776323   PMID:11818362  
PMID:11866539   PMID:12114510   PMID:12192306   PMID:12600825   PMID:12777947   PMID:14610081   PMID:15201552   PMID:15328353   PMID:15728787   PMID:15808835   PMID:15853774   PMID:16862142  
PMID:17394767   PMID:17396111   PMID:17655862   PMID:17953365   PMID:18367662   PMID:18471418   PMID:18554148   PMID:18636553   PMID:18664599   PMID:18761555   PMID:18835034   PMID:18974388  
PMID:19246637   PMID:19306296   PMID:19403340   PMID:19625379   PMID:19718486   PMID:19855083   PMID:19887897   PMID:19916862   PMID:20538356   PMID:21036181   PMID:21119013   PMID:21193004  
PMID:21276792   PMID:21355198   PMID:21412817   PMID:21613793   PMID:21752621   PMID:21829547   PMID:22071631   PMID:22556277   PMID:23016136   PMID:23021499   PMID:23218127   PMID:23979707  
PMID:24006456   PMID:24913911   PMID:25106729   PMID:25342286   PMID:26415098   PMID:27046084   PMID:27456456   PMID:28337441   PMID:28722352   PMID:29644896   PMID:30449218   PMID:30982977  
PMID:31257474   PMID:32748313   PMID:33450132   PMID:35352799  


Genomics

Comparative Map Data
Serpine1
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81225,237,977 - 25,248,356 (+)NCBIGRCr8
mRatBN7.21219,601,272 - 19,611,657 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1219,601,272 - 19,611,657 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1220,739,113 - 20,749,506 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01221,351,819 - 21,362,213 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01220,416,358 - 20,426,756 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01222,641,104 - 22,651,482 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1222,641,104 - 22,651,482 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01224,653,385 - 24,663,763 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41220,931,996 - 20,942,374 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11220,921,607 - 20,931,986 (-)NCBI
Celera1221,377,028 - 21,387,410 (+)NCBICelera
RH 3.4 Map12277.5RGD
Cytogenetic Map12q12NCBI
SERPINE1
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh387101,127,104 - 101,139,247 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl7101,127,104 - 101,139,247 (+)EnsemblGRCh38hg38GRCh38
GRCh377100,770,385 - 100,782,528 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 367100,557,172 - 100,569,026 (+)NCBINCBI36Build 36hg18NCBI36
Build 347100,363,886 - 100,375,741NCBI
Celera795,778,744 - 95,790,926 (+)NCBICelera
Cytogenetic Map7q22.1NCBI
HuRef795,363,553 - 95,375,745 (+)NCBIHuRef
CHM1_17100,700,705 - 100,712,867 (+)NCBICHM1_1
T2T-CHM13v2.07102,449,908 - 102,462,056 (+)NCBIT2T-CHM13v2.0
CRA_TCAGchr7v27100,128,757 - 100,140,934 (+)NCBI
Serpine1
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm395137,090,358 - 137,101,126 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl5137,090,358 - 137,101,122 (-)EnsemblGRCm39 Ensembl
GRCm385137,061,504 - 137,072,272 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl5137,061,504 - 137,072,268 (-)EnsemblGRCm38mm10GRCm38
MGSCv375137,537,374 - 137,548,142 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv365137,346,135 - 137,356,886 (-)NCBIMGSCv36mm8
Celera5134,078,340 - 134,089,224 (-)NCBICelera
Cytogenetic Map5G2NCBI
cM Map576.16NCBI
Serpine1
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495545616,145,944 - 16,157,142 (-)EnsemblChiLan1.0
ChiLan1.0NW_00495545616,147,523 - 16,157,040 (-)NCBIChiLan1.0ChiLan1.0
SERPINE1
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v26119,139,033 - 119,151,584 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan17167,403,992 - 167,416,224 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0793,267,517 - 93,279,728 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.17106,511,539 - 106,518,605 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl7106,510,130 - 106,518,450 (+)Ensemblpanpan1.1panPan2
SERPINE1
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.168,719,547 - 8,727,160 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl68,720,825 - 8,726,301 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha610,418,147 - 10,423,482 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.068,538,810 - 8,546,429 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl68,540,391 - 8,550,490 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.168,500,159 - 8,505,509 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.068,470,611 - 8,475,963 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.068,635,341 - 8,640,693 (-)NCBIUU_Cfam_GSD_1.0
Serpine1
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024409344132,997,052 - 133,003,714 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365431,032,794 - 1,039,123 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049365431,032,543 - 1,040,956 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
SERPINE1
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl38,863,695 - 8,871,547 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.138,863,738 - 8,871,572 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
SERPINE1
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.12812,047,520 - 12,060,662 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl2812,047,529 - 12,060,202 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_0236660704,295,672 - 4,308,796 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Serpine1
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_00462474016,128,059 - 16,137,337 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462474016,128,145 - 16,136,696 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Serpine1
61 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:814
Count of miRNA genes:305
Interacting mature miRNAs:394
Transcripts:ENSRNOT00000001916
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
2312418Kidm41Kidney mass QTL 413.70.0001kidney mass (VT:0002707)single kidney wet weight to body weight ratio (CMO:0000622)12119611090Rat
10755457Coatc14Coat color QTL 140.01759coat/hair pigmentation trait (VT:0010463)pigmented ventral coat/hair area to total ventral coat/hair area ratio (CMO:0001812)12122591684Rat
6893681Bw109Body weight QTL 1092.30.004body mass (VT:0001259)body weight (CMO:0000012)12123297788Rat
1581516Cm56Cardiac mass QTL 564.20.05heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)12129333307Rat
1598855Bp294Blood pressure QTL 2943.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)12134851688Rat
7411660Foco28Food consumption QTL 2810.90.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12142110980Rat
9590086Insglur6Insulin/glucose ratio QTL 618.970.001blood insulin amount (VT:0001560)calculated plasma insulin level (CMO:0002170)12142110980Rat
8694179Bw150Body weight QTL 1502.90.001body mass (VT:0001259)body weight gain (CMO:0000420)12142110980Rat
7411586Foco5Food consumption QTL 55.40.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12142110980Rat
7411595Foco9Food consumption QTL 940.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12142110980Rat
7411545Bw128Body weight QTL 1285.20.001body mass (VT:0001259)body weight gain (CMO:0000420)12142110980Rat
9590147Scort7Serum corticosterone level QTL 713.610.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)12142110980Rat
2303575Insul14Insulin level QTL 144blood insulin amount (VT:0001560)blood insulin level (CMO:0000349)12142450532Rat
737979Pia22Pristane induced arthritis QTL 2253.1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)12144465750Rat
634351Apr5Acute phase response QTL 56.7blood interleukin-6 amount (VT:0008595)plasma interleukin-6 level (CMO:0001927)12144503507Rat
2302042Pia38Pristane induced arthritis QTL 383.50.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)12144503507Rat
634350Apr4Acute phase response QTL 46orosomucoid 1 amount (VT:0010541)plasma orosomucoid 1 level (CMO:0001467)12117200546172005Rat
8552918Pigfal7Plasma insulin-like growth factor 1 level QTL 7blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)12556449546669029Rat
7411547Bw129Body weight QTL 1290.001body mass (VT:0001259)body weight gain (CMO:0000420)6556449546669029Rat
7411597Foco10Food consumption QTL 100.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12556449546669029Rat
7411641Foco19Food consumption QTL 1927.70.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12556449546669029Rat
8552964Pigfal17Plasma insulin-like growth factor 1 level QTL 173.5blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)12556449546669029Rat
7411588Foco6Food consumption QTL 60.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12556449546669029Rat
8552912Pigfal6Plasma insulin-like growth factor 1 level QTL 65blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)12556449846669029Rat
10059594Kidm46Kidney mass QTL 463.790.025kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)12610757946669029Rat
1302792Scl21Serum cholesterol level QTL 213.80.0011blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)12719673046669029Rat
2293086Iddm30Insulin dependent diabetes mellitus QTL 303.82blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)12844949028302290Rat
61331Eau2Experimental allergic uveoretinitis QTL 20.0005uvea integrity trait (VT:0010551)experimental autoimmune uveitis score (CMO:0001504)12852542328064601Rat
1300157Rf21Renal function QTL 214.4renal blood flow trait (VT:2000006)absolute change in renal blood flow rate (CMO:0001168)12931821632103380Rat
1549829Scl48Serum cholesterol level QTL 485blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)12960327746669029Rat
2293699Bss49Bone structure and strength QTL 495.610.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra trabecular cross-sectional area (CMO:0001692)121047413746669029Rat
2300186Bmd59Bone mineral density QTL 597.10.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)121047413746669029Rat
1331786Kidm11Kidney mass QTL 113.571kidney mass (VT:0002707)right kidney wet weight (CMO:0000082)121107382524234895Rat
1331755Bp219Blood pressure QTL 2193.041arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)121107382528064557Rat
1331761Bp218Blood pressure QTL 2182.973arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)121107382545055165Rat
61404Bw120Body weight QTL 1205.1body mass (VT:0001259)body mass index (BMI) (CMO:0000105)121235161946669029Rat
1641928Alcrsp5Alcohol response QTL 5response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)121281238546669029Rat
2303569Gluco44Glucose level QTL 442blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)121281238546669029Rat
1549902Bp269Blood pressure QTL 269arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)121318273646669029Rat
1549912Bp268Blood pressure QTL 268arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)101318273646669029Rat
2302060Pia37Pristane induced arthritis QTL 376.10.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)121319815746669029Rat
61416Pia4Pristane induced arthritis QTL 48.4joint integrity trait (VT:0010548)arthritic paw count (CMO:0001460)121363552330827399Rat
61421Cia12Collagen induced arthritis QTL 124.6joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)121363552335682913Rat
61443Btemp2Thermal response to stress QTL 23.30.000094body temperature trait (VT:0005535)core body temperature (CMO:0001036)121502518320794014Rat
631543Bp83Blood pressure QTL 835.8arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)121555082638478808Rat
2293684Bmd26Bone mineral density QTL 264.40.0002femur mineral mass (VT:0010011)total volumetric bone mineral density (CMO:0001728)121587265332974238Rat
631560Apr1Acute phase response QTL 16.1orosomucoid 1 amount (VT:0010541)plasma orosomucoid 1 level (CMO:0001467)121914436246669029Rat
2306789Ean6Experimental allergic neuritis QTL 64.9nervous system integrity trait (VT:0010566)experimental autoimmune neuritis severity score (CMO:0001528)121961087024139202Rat
737822Alc10Alcohol consumption QTL 102.2consumption behavior trait (VT:0002069)ethanol drink intake rate (CMO:0001407)121961087040218516Rat
5684888Pia42Pristane induced arthritis QTL 42joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)121961087042828880Rat
61324Eae5Experimental allergic encephalomyelitis QTL 514nervous system integrity trait (VT:0010566)percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time (CMO:0001402)121961087046669029Rat
1298081Cia25Collagen induced arthritis QTL 254.7joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)121961088935682913Rat

Markers in Region
D12Mit2  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21219,610,870 - 19,611,091 (+)MAPPERmRatBN7.2
Rnor_6.01222,650,702 - 22,650,918NCBIRnor6.0
Rnor_5.01224,662,983 - 24,663,199UniSTSRnor5.0
RGSC_v3.41220,932,560 - 20,932,776UniSTSRGSC3.4
RGSC_v3.41220,932,559 - 20,932,776RGDRGSC3.4
RGSC_v3.11220,922,171 - 20,922,388RGD
Celera1221,386,630 - 21,386,846UniSTS
RH 3.4 Map12280.3RGD
RH 3.4 Map12280.3UniSTS
RH 2.0 Map12205.1RGD
SHRSP x BN Map1222.7RGD
FHH x ACI Map129.01RGD
Cytogenetic Map12q11-q12UniSTS
D12Wox11  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21219,610,886 - 19,611,090 (+)MAPPERmRatBN7.2
Rnor_6.01222,650,718 - 22,650,917NCBIRnor6.0
Rnor_5.01224,662,999 - 24,663,198UniSTSRnor5.0
RGSC_v3.41220,932,561 - 20,932,760UniSTSRGSC3.4
RGSC_v3.41220,932,560 - 20,932,760RGDRGSC3.4
RGSC_v3.11220,922,172 - 20,922,372RGD
Celera1221,386,646 - 21,386,845UniSTS
RH 3.4 Map12277.7UniSTS
RH 3.4 Map12277.7RGD
RH 2.0 Map12206.8RGD
Cytogenetic Map12q11-q12UniSTS
D12Wox12  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21219,610,889 - 19,611,095 (+)MAPPERmRatBN7.2
Rnor_6.01222,650,721 - 22,650,922NCBIRnor6.0
Rnor_5.01224,663,002 - 24,663,203UniSTSRnor5.0
RGSC_v3.41220,932,556 - 20,932,757UniSTSRGSC3.4
RGSC_v3.41220,932,555 - 20,932,757RGDRGSC3.4
RGSC_v3.11220,922,167 - 20,922,369RGD
Celera1221,386,649 - 21,386,850UniSTS
RH 3.4 Map12277.5UniSTS
RH 3.4 Map12277.5RGD
RH 2.0 Map12197.1RGD
Cytogenetic Map12q11-q12UniSTS
D12Arb4   No map positions available.
RH129692  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21219,611,385 - 19,611,585 (+)MAPPERmRatBN7.2
Rnor_6.01222,651,211 - 22,651,410NCBIRnor6.0
Rnor_5.01224,663,492 - 24,663,691UniSTSRnor5.0
RGSC_v3.41220,932,068 - 20,932,267UniSTSRGSC3.4
Celera1221,387,139 - 21,387,338UniSTS
RH 3.4 Map12277.5UniSTS
Cytogenetic Map12q11-q12UniSTS
RH142420  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21219,610,381 - 19,610,594 (+)MAPPERmRatBN7.2
Rnor_6.01222,650,213 - 22,650,425NCBIRnor6.0
Rnor_5.01224,662,494 - 24,662,706UniSTSRnor5.0
RGSC_v3.41220,933,053 - 20,933,265UniSTSRGSC3.4
Celera1221,386,141 - 21,386,353UniSTS
RH 3.4 Map12277.5UniSTS
Cytogenetic Map12q11-q12UniSTS
RH94577  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21219,611,229 - 19,611,407 (+)MAPPERmRatBN7.2
Rnor_6.01222,651,055 - 22,651,232NCBIRnor6.0
Rnor_5.01224,663,336 - 24,663,513UniSTSRnor5.0
RGSC_v3.41220,932,246 - 20,932,423UniSTSRGSC3.4
Celera1221,386,983 - 21,387,160UniSTS
Cytogenetic Map12q11-q12UniSTS
PMC15197P3  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21219,609,566 - 19,610,072 (+)MAPPERmRatBN7.2
Rnor_6.01222,649,398 - 22,649,903NCBIRnor6.0
Rnor_5.01224,661,679 - 24,662,184UniSTSRnor5.0
RGSC_v3.41220,933,575 - 20,934,080UniSTSRGSC3.4
Celera1221,385,326 - 21,385,831UniSTS
Cytogenetic Map12q11-q12UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 1 16 3 3 9 5
Low 2 27 48 35 19 35 8 11 66 32 32 6 8
Below cutoff 6 6 6 8

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000001916   ⟹   ENSRNOP00000001916
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1219,601,272 - 19,611,657 (+)Ensembl
Rnor_6.0 Ensembl1222,641,104 - 22,651,482 (+)Ensembl
RefSeq Acc Id: NM_012620   ⟹   NP_036752
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81225,237,977 - 25,248,356 (+)NCBI
mRatBN7.21219,601,272 - 19,611,657 (+)NCBI
Rnor_6.01222,641,104 - 22,651,482 (+)NCBI
Rnor_5.01224,653,385 - 24,663,763 (+)NCBI
RGSC_v3.41220,931,996 - 20,942,374 (-)RGD
Celera1221,377,028 - 21,387,410 (+)RGD
Sequence:
Protein Sequences
Protein RefSeqs NP_036752 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAA41796 (Get FASTA)   NCBI Sequence Viewer  
  AAA56856 (Get FASTA)   NCBI Sequence Viewer  
  EDM13286 (Get FASTA)   NCBI Sequence Viewer  
Ensembl Protein ENSRNOP00000001916
  ENSRNOP00000001916.2
  ENSRNOP00055000151
  ENSRNOP00060016231
  ENSRNOP00065001504
GenBank Protein P20961 (Get FASTA)   NCBI Sequence Viewer  
Reference Protein Sequences
RefSeq Acc Id: NP_036752   ⟸   NM_012620
- Peptide Label: precursor
- UniProtKB: P20961 (UniProtKB/Swiss-Prot),   F1LM16 (UniProtKB/TrEMBL),   A6J047 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000001916   ⟸   ENSRNOT00000001916
Protein Domains
SERPIN

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P20961-F1-model_v2 AlphaFold P20961 1-402 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13698524
Promoter ID:EPDNEW_R9049
Type:multiple initiation site
Name:Serpine1_1
Description:serpin family E member 1
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01222,641,079 - 22,641,139EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:3249 AgrOrtholog
BioCyc Gene G2FUF-19678 BioCyc
Ensembl Genes ENSRNOG00000001414 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
  ENSRNOG00055000166 UniProtKB/Swiss-Prot
  ENSRNOG00060012143 UniProtKB/Swiss-Prot
  ENSRNOG00065001606 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000001916 ENTREZGENE
  ENSRNOT00000001916.3 UniProtKB/TrEMBL
  ENSRNOT00055000256 UniProtKB/Swiss-Prot
  ENSRNOT00060020611 UniProtKB/Swiss-Prot
  ENSRNOT00065002155 UniProtKB/Swiss-Prot
Gene3D-CATH 2.30.39.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  3.30.497.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Serpin_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Serpin_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Serpin_fam UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Serpin_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Serpin_sf_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Serpin_sf_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:24617 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
NCBI Gene 24617 ENTREZGENE
PANTHER PLASMINOGEN ACTIVATOR INHIBITOR 1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR11461 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Serpin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PharmGKB SERPINE1 RGD
PhenoGen Serpine1 PhenoGen
PROSITE SERPIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000001414 RatGTEx
  ENSRNOG00055000166 RatGTEx
  ENSRNOG00060012143 RatGTEx
  ENSRNOG00065001606 RatGTEx
SMART SERPIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF56574 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A6J047 ENTREZGENE, UniProtKB/TrEMBL
  F1LM16 ENTREZGENE, UniProtKB/TrEMBL
  P20961 ENTREZGENE, UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2016-04-13 Serpine1  serpin family E member 1  Serpine1  serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2011-01-19 Serpine1  serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1  Serpine1  serine (or cysteine) peptidase inhibitor, clade E, member 1  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2006-03-30 Serpine1  serine (or cysteine) peptidase inhibitor, clade E, member 1    serine (or cysteine) proteinase inhibitor, clade E, member 1  Name updated 1299863 APPROVED
2004-12-14 Serpine1  serine (or cysteine) proteinase inhibitor, clade E, member 1    serine (or cysteine) proteinase inhibitor, member 1  Name updated 1299863 APPROVED
2003-05-08 Serpine1  serine (or cysteine) proteinase inhibitor, member 1      Symbol and Name updated to reflect Human and Mouse nomenclature 61478 PROVISIONAL
2002-06-10 Pai1  serine (or cysteine) proteinase inhibitor, member 1      Name updated 70585 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_expression expression induced during hepatocyte regeneration after liver injury 70249
gene_expression found in plasma and platelets and in endothelial, hepatoma, and fibrosarcoma cells 61489
gene_physical_interaction interacts with tissue plasminogen activator, urokinase, and protein c  
gene_process may function as a major control point in the regulation of fibrinolysis  
gene_product acid-stable glycoprotein 61489